Clinuvel Pharmaceuticals (ASX: CUV) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Clinuvel Pharmaceuticals Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Clinuvel Pharmaceuticals (ASX: CUV)
Latest News
Share Gainers
Why CLINUVEL and these ASX shares have doubled in value in 12 months
Share Fallers
Why Clinuvel, Myer, Pro Medicus, & Wesfarmers shares tumbled lower today
Share Market News
Bell Potter upgrades Clinuvel Pharmaceuticals Limited to a buy
Share Gainers
Why Cann, Clinuvel, Nufarm, & Ramelius shares stormed higher today
Share Gainers
ALL ORDINARIES finishes lower Wednesday: 8 shares you missed
Share Fallers
Why the Clinuvel Pharmaceuticals share price plunged 26% lower today
Share Gainers
Why the Clinuvel share price has tripled in value in just 12 months
52-Week Highs
Why Clinuvel and 2 other ASX shares just stormed to 52-week highs
Growth Shares
How you could have turned $10,000 into $370,000 in five years on the ASX
⏸️ Diversification
5 ASX shares I would buy with $20,000 to set up a diversified portfolio
52-Week Highs
The Clinuvel share price has hit an all-time high and is up 188% in 12 months
Share Gainers
Why the Clinuvel share price is up 150% over the past year
Frequently Asked Questions
-
Yes, Clinuvel Pharmaceuticals has historically paid one unfranked shareholder dividend a year.
-
Clinuvel Pharmaceuticals generally pays its shareholder dividend in September.
-
Clinuvel Pharmaceuticals does not have a dividend reinvestment plan.
-
Clinuvel Pharmaceuticals Limited listed on the ASX on 13 February 2001.
CUV ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Ltd (ASX: CUV) is an Australian-based global biopharmaceutical company developing drugs for the treatment of genetic and vascular disorders. Its principal product SCENESSE is a drug for an inherited disorder, erythropoietic protoporphyria, that causes an intolerance to light.
Its pioneering work aims at preventing the symptoms of skin diseases related to exposure to UV radiation and at repigmentation of the skin due to depigmentation disorders. Geographically, the company derives the majority of its revenue from its US and European markets.
